Résumé :
|
The overall objective of the Quality Medicines for Reproductive Health Project is to improve access to essential reproductive health (RH) medicines and commodities by promoting global standards, developing guidance on assured quality suppliers and products, and building procurement capacity in resource-limited countries. In the past year, interagency consultations had been held between United Nations (UN) agencies and nongovernmental organizations (NGOs) working in the field of RH to finalize jointly the Essential List for RH medicines and commodities. Discrepant medicines1 on UN RH lists were identified and decisions made (based on preliminary reviews) either to delete them from all RH lists and guidelines or to review them formally for possible addition to the Model List. For example, tinidazole will be deleted from the clinical guidelines as metronidazole is the first-line treatment for trichomoniasis. Other medicines, such as cefixime and misoprostol, were formally submitted and reviewed for possible addition to the WHO Model List of Essential Medicines. Sixteen RH medicines were reviewed during the 14th Expert Committee Meeting on the Selection and Use of Essential Medicines.
|